Newsletter

Subscribe and recieve updates on this company.

Text STOCKS to 72727 for mobile alerts

We are excited to present Wave Life Sciences Ltd. (NASDAQ: WVE).

Full DD Report for WVE

You must become a subscriber to view this report.


Recent News from (NASDAQ: WVE)

Oryzon Genomics commences mid-stage study of Alzheimer's candidate
Spanish biotech Oryzon Genomics announces that enrollment is underway in a Phase 2b clinical trial assessing ORY-2001 in patients with mild-to-moderate Alzheimer's disease (AD). More news on: vTv Therapeutics, Biogen Inc., Tonix Pharmaceuticals Holding Corp., Healthcare stocks news, ...
Source: SeekingAlpha
Date: May, 14 2018 12:27
Institutional Top Ideas Series: Ra Capital Management
In the last entry of this series we took a look at top ideas from Orbimed Advisors, a large fund in the midst of a leadership transition which avoids outsized bets (over 5% weighting) yet still has posted decent returns. Going forward, I hope to continue to delve into the portfolios of su...
Source: SeekingAlpha
Date: May, 10 2018 02:04
Wave Life Sciences reports Q1 results
Wave Life Sciences (NASDAQ: WVE ): Q1 EPS of -$1.26 More news on: Wave Life Sciences, Earnings news and commentary, Healthcare stocks news, Read more ...
Source: SeekingAlpha
Date: May, 09 2018 08:09
Wave Life Sciences Reports First Quarter 2018 Financial Results and Provides Business Update
CAMBRIDGE, Mass., May 09, 2018 (GLOBE NEWSWIRE) -- Wave Life Sciences Ltd. (NASDAQ:WVE), a biotechnology company focused on delivering transformational therapies for patients with serious, genetically-defined diseases, today announced financial results for the first quarter ended March 31, ...
Source: GlobeNewswire
Date: May, 09 2018 08:00
Pushing Preclinical: Wave Of Early-Stage Biotech IPOs Tests Investor Risk Appetite
Biotechs are among the most risky of IPOs due to the binary nature of the success… or failure of their drugs. In the past, most biotechs delayed public offerings until they at least showed clinical evidence of their safety or efficacy. But in 2018, biotechs are increasingly going publ...
Source: SeekingAlpha
Date: May, 09 2018 05:37
Your Daily Pharma Scoop: Synergy Activism, Pfizer Wave Sciences Collaboration, Agenus Update
Analysis focus: SGYP Synergy Pharma (SGYP), ever the laggard, and the bane of many a portfolio, suddenly saw a bit of movement yesterday on the back of news that a group of activist investor s have taken up the cudgel against the management of Synergy. These investors have written to a nu...
Source: SeekingAlpha
Date: May, 08 2018 03:34
Wave Life Sciences Highlights Progress on Hepatic Collaboration with Pfizer
With the designation of five targets, Pfizer nominates the maximum permitted under collaboration Collaboration moving toward candidate selection CAMBRIDGE, Mass., May 07, 2018 (GLOBE NEWSWIRE) -- Wave Life Sciences Ltd. (NASDAQ:WVE), a biotechnology company focused on delivering tr...
Source: GlobeNewswire
Date: May, 07 2018 08:00
Solid Biosciences moving closer to removal of clinical hold on early-stage study of DMD candidate SGT-001; shares up 6%
Thinly traded Solid Biosciences ( SLDB +5.5% ) is up, albeit on turnover of only 85K shares, on its announcement that it has received a letter from FDA concerning the full clinical hold on its Phase 1/2 study of gene therapy SGT-001 in patients with Duchenne muscular dystrophy. The agenc...
Source: SeekingAlpha
Date: April, 30 2018 13:43
Capricor launches mid-stage study of DMD candidate CAP-1002; shares up 2%
Capricor Therapeutics ( CAPR +1.5% ) initiates a Phase 2 clinical trial, HOPE-2 , assessing CAP-1002 in boys and young men with Duchenne muscular dystrophy (DMD). More news on: Capricor Therapeutics, Inc., Sarepta Therapeutics, Inc., Catabasis Pharmaceuticals, Healthcare stocks news, ...
Source: SeekingAlpha
Date: April, 30 2018 13:23
Wave Life Sciences to Present Data on ALS and FTD Programs and on Huntington's Disease at the 2018 American Academy of Neurology Annual Meeting
CAMBRIDGE, Mass., April 17, 2018 (GLOBE NEWSWIRE) -- Wave Life Sciences Ltd. (NASDAQ:WVE), a biotechnology company focused on delivering transformational therapies for patients with serious, genetically-defined diseases, will present key data on its amyotrophic lateral sclerosis (ALS) an...
Source: GlobeNewswire
Date: April, 17 2018 08:00

 


Last 5 Days Trading Activity

DateOpen PriceClose PriceHighLowVolume
2018-05-1741.4543.0544.2041.45186,738
2017-03-1027.2026.9527.2026.802,845
2017-03-0927.3027.0027.3026.3051,074
2017-03-0827.1027.0027.3026.4052,186
2017-03-0726.7527.0027.9526.4061,992

Last 5 Days Short Activity

DateShort VolumeTotal VolumeShort PercentageShort Indicator
2018-08-212,0263,08065.7792Short
2018-08-202,2713,90958.0967Short
2018-08-176,1248,52971.8021Short
2018-08-1610,75713,38980.3421Short
2018-08-155,90224,23624.3522Cover

* Short Mode

Short Analysis provided by Squeeze Report. Get a complete short report on WVE.


About Wave Life Sciences Ltd. (NASDAQ: WVE)

Logo for Wave Life Sciences Ltd. (NASDAQ: WVE)

Not available

 

Contact Information

 

 

Current Share Structure

  • Market Cap: $1,097,295,965 - 05/11/2018
  • Issue and Outstanding: 27,992,244 - 03/01/2018

 


Recent Filings from (NASDAQ: WVE)

Report of unscheduled material events or corporate changes.
Filing Type: 8-KFiling Source: edgar
Filing Date: May, 09 2018
Amendment to a previously filed 10-K
Filing Type: 10-K/AFiling Source: edgar
Filing Date: May, 09 2018
Quarterly report with a continuing view of a company's financial position
Filing Type: 10-QFiling Source: edgar
Filing Date: May, 09 2018
Amendment to a previously filed 10-K
Filing Type: 10-K/AFiling Source: edgar
Filing Date: April, 27 2018
Amendment to a SC 13D filing
Filing Type: SC 13D/AFiling Source: edgar
Filing Date: April, 26 2018
Report of unscheduled material events or corporate changes.
Filing Type: 8-KFiling Source: edgar
Filing Date: April, 10 2018
Report of unscheduled material events or corporate changes.
Filing Type: 8-KFiling Source: edgar
Filing Date: April, 02 2018
Report of unscheduled material events or corporate changes.
Filing Type: 8-KFiling Source: edgar
Filing Date: March, 26 2018
Amendment to a SC 13D filing
Filing Type: SC 13D/AFiling Source: edgar
Filing Date: March, 22 2018
Report of unscheduled material events or corporate changes.
Filing Type: 8-KFiling Source: edgar
Filing Date: March, 12 2018

 

 


Daily Technical Chart for (NASDAQ: WVE)

Daily Technical Chart for (NASDAQ: WVE)


Stay tuned for daily updates and more on (NASDAQ: WVE)

It most certainly could but even more important is the recent overwhelming interest in the company. Check out Investors Hub and search on Twitter

More to come on (NASDAQ: WVE)

Do your DD and if you choose, be ready to go!


 

The Research: All source information contained in this email is from the public sources mentioned below.

 

 
 

Thank you

DD Report
@DDReports

 

 


Disclaimer: DD Report publishes reports providing information on selected companies. DD Report is not a registered investment advisor or broker-dealer. This report is provided as an information service only, and the statements and opinions in this report should not be construed as an offer or solicitation to buy or sell any security. DD Report accepts no liability for any loss arising from an investors reliance on or use of this report. An investment in WVE is considered to be highly speculative and should not be considered unless a person can afford a complete loss of investment. DD Report has received up to $100,000 worth of crypto currency from a non-affiliated third party for the publication and circulation of this report. DD Report does not own any shares of WVE and does not buy, sell, or trade any shares of WVE. This report contains forward-looking statements, which involve risks, and uncertainties that may cause actual results to differ materially from those set forth in the forward-looking statements. Copyright 2018 by DD Report. All rights reserved. Our Full Disclaimer: http://dd.report/disclaimer/